Atherosclerosis is a chronic progressive inflammatory disease of the large and medium-
sized artery walls. The molecular mechanisms regulating the onset and progression of …

Atherosclerosis is a leading cause of cardiovascular diseases (CVD) worldwide and
intimately linked to aging. This pathology is characterized by chronic inflammation, oxidative …

Background The immune system plays a vital role in the pathological process of ischaemic
stroke. However, the exact immune-related mechanism remains unclear. The current …

Immune-related adverse events (irAEs) are toxicities that arise after the administration of
monoclonal antibodies targeting immune checkpoints (immune checkpoint inhibitors [ICIs]) …

Atherosclerotic cardiovascular disease (ASCVD) is a chronic inflammatory disease of the
arterial walls and is characterized by the accumulation of lipoproteins that are insufficiently …

Novel therapeutic options have significantly improved survival and long-term outcomes in
many cancer entities. Unfortunately, this improvement in outcome is often accompanied by …

The advent of immunological therapies has revolutionized the treatment of solid and
haematological cancers over the last decade. Licensed therapies which activate the immune …

Immune checkpoint inhibitors (ICIs) are specialized monoclonal antibodies (mAbs) that
target immune checkpoints and their ligands, counteracting cancer cell-induced T-cell …

The benefits of current state-of-the-art treatments to combat atherosclerotic cardiovascular
disease (ASCVD) have stagnated. Treatments are mostly based on controlling …

Background While immune checkpoint inhibitors (ICIs) are associated with elevated
cardiovascular risks, evidence of any association between ICIs and myocardial infarction …